Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06818695

Online Imaginal Exposure Therapy for Eating Disorders Trial

Efficacy of Online Imaginal Exposure Therapy for Individuals With Anorexia Nervosa

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
76 (estimated)
Sponsor
University College, London · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to learn if an imaginal exposure intervention first conducted by Levinson and colleagues (2020) can produce similar promising results in individuals with anorexia on the waiting list of an NHS eating disorder service. The main question it aims to answer is: 1. How effective is Imaginal Exposure Therapy in reducing eating disorder symptoms and increasing weight in patients with AN? The secondary research questions are: 2. How effective is Imaginal Exposure Therapy in reducing anxiety and fear related outcomes around food and eating? 3. How effective is Imaginal Exposure Therapy in improving patients' general anxiety and depression symptoms? Researchers will compare the results of individuals in the treatment condition to individual's in the control condition to explore the efficacy of the intervention on eating disorder and eating disorder fear symptomology, and body weight. Participants in the intervention group will receive 4 sessions of online exposure therapy, and participants in the control group will remain on the waiting list with treatment as usual (primarily nurse monitoring).

Detailed description

Study design type: The study will have a parallel group design. Approximately half of the participants will be randomised to receive our intervention, IE for AN. The other half will remain on the waitlist for the service and receive treatment as usual (TAU), which includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs). This study design will allow us to directly assess the efficacy of the IE intervention, as compared to standard waiting list monitoring, on participants' weight and AN symptoms. Sampling: Potential participants will be identified by the direct care team; any details not obtained through the study questionnaires will be obtained through digital medical records. The researchers will request information where needed through the direct care team. Participants will be recruited through the NELFT ED service post referral triage, while patients are on the waiting list. Participants will be the adults on the waiting list for receiving AN treatment at NELFT. Procedure: Following informed consent, participation in the trial will last 5 weeks. Week 1: All participants will, where possible, come to the service in-person to be weighed. All participants will complete a set of psychometric questionnaires during this appointment. The IE group will also complete the Eating Disorder Fear Interview (Levinson et al., 2019), administered in order to identify a fear to target in exposure therapy. If not possible to attend in-person, this primary appointment will be held on Zoom. All baseline appointments will be with a study coordinator. Week 2: First online imaginal exposure. Week 3: Second online imaginal. Week 4: Third online imaginal exposure. Week 5: Fourth online imaginal exposure and participants will complete the final battery of online questionnaires. They will then come to the service in-person to be weighed again.

Conditions

Interventions

TypeNameDescription
OTHERImaginal Exposure for Anorexia NervosaImaginal exposure aims to use the power of imagining the fearful situation to heighten anxiety and by not engaging in imaginative restriction or other eating disorder behaviours, the individual, in theory, can habituate to the anxiety until it naturally subsides.
OTHERTreatment as Usual (TAU)TAU includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs)

Timeline

Start date
2025-04-01
Primary completion
2026-04-01
Completion
2026-06-01
First posted
2025-02-10
Last updated
2025-04-06

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT06818695. Inclusion in this directory is not an endorsement.